Evidence for Interference With the Intestinal Absorption of Levothyroxine Sodium by Aluminum Hydroxide

Ami D. Sperber, Yair Liel

    Research output: Contribution to journalArticlepeer-review

    70 Scopus citations

    Abstract

    A patient with hypothyroidism who was euthyroid on a fixed-dosage, long-term maintenance regimen of levothyroxine sodium developed persistently elevated serum thyrotropin levels while receiving an aluminum hydroxide— containing antacid. The thyrotropin levels returned to normal shortly after cessation of the antacid therapy. These observations indicate that aluminum hydroxide may interfere with the bioavailability of thyroxine. The thyroid function of patients who are receiving replacement or suppressive thyroxine therapy should be monitored following the commencement of concurrent treatment with medications containing aluminum hydroxide.

    Original languageEnglish
    Pages (from-to)183-184
    Number of pages2
    JournalArchives of Internal Medicine
    Volume152
    Issue number1
    DOIs
    StatePublished - 1 Jan 1992

    ASJC Scopus subject areas

    • Internal Medicine

    Fingerprint

    Dive into the research topics of 'Evidence for Interference With the Intestinal Absorption of Levothyroxine Sodium by Aluminum Hydroxide'. Together they form a unique fingerprint.

    Cite this